|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||






Department of
* Neurosurgery, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA;
Department of Dermatology, Boston University School of Medicine, Boston, Massachusetts, USA; Departments of
Biostatistics and Applied Mathematics and
Molecular Therapeutics, The University of Texas M. D. Anderson Cancer Center;
|| Department of Neurosurgery, Baylor College of Medicine; and
¶ The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, Texas, USA
2Correspondence: Department of Neurosurgery, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Unit BSRB 1004, Houston, TX 77030, USA. E-mail: seikondo{at}mdanderson.org.
Telomere 3' overhang-specific DNA oligonucleotides (T-oligos) induce cell death in cancer cells, presumably by mimicking telomere loop disruption. Therefore, T-oligos are considered an exciting new therapeutic strategy. The purpose of this study was to elucidate how T-oligos exert antitumor effects on human malignant glioma cells in vitro and in vivo. We demonstrated that T-oligos inhibited the proliferation of malignant glioma cells through induction of nonapoptotic cell death and mitochondria hyperpolarization, whereas normal astrocytes were resistant to T-oligos. Tumor cells treated with T-oligos developed features compatible with autophagy, with development of autophagic vacuoles and conversion of an autophagy-related protein, microtubule-associated protein 1 light chain 3 from type I (cytoplasmic form) to type II (membrane form of autophagic vacuoles). A reverse-phase protein microarray analysis and Western blotting revealed that treatment with T-oligos inhibited the mammalian target of the rapamycin (mTOR) and the signal transducer and activator of transcription 3 (STAT3). Moreover, pretreatment with T-oligos significantly prolonged the survival time of mice inoculated intracranially with malignant glioma cells compared with that of untreated mice and those treated with control oligonucleotides (P=0.0065 and P=0.043, respectively). These results indicate that T-oligos stimulate the induction of nonapoptotic autophagic also known as type II programmed cell death and are thus promising in the treatment of malignant glioma.—Aoki, H., Iwado, E., Eller, M. S., Kondo, Y., Fujiwara, K., Li, G.-Z., Hess, K. R., Siwak, D. R., Sawaya, R., Mills, G. B., Gilchrest, B. A., Kondo, S. Telomere 3' overhang-specific DNA oligonucleotides induce autophagy in malignant glioma cells.
Key Words: T-oligos mTOR
This article has been cited by other articles:
![]() |
S. Arad, E. Zattra, J. Hebert, E. H. Epstein Jr., D. A. Goukassian, and B. A. Gilchrest Topical Thymidine Dinucleotide Treatment Reduces Development of Ultraviolet-Induced Basal Cell Carcinoma in Ptch-1+/- Mice Am. J. Pathol., May 1, 2008; 172(5): 1248 - 1255. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |